Table 1.
Characteristics of 501 patients with marginal zone lymphoma at time of treatment.
| Group | Treated n (%) |
Treated after W&W |
p | Overall |
|---|---|---|---|---|
| n = 435 | n = 66 | n (%) | ||
| Age | ||||
| <70 years | 259 (60) | 28 (42) | 0.011 | 287 (57) |
| ≥70 years | 176 (40) | 38 (58) | 214 (43) | |
| Stage | ||||
| I–II | 90 (21) | 5 (8) | 0.007 | 95 (19) |
| III–IV | 338 (79) | 61 (92) | 399 (81) | |
| Missing | 7 | – | 7 | |
| Bone marrow | ||||
| Negative | 183 (44) | 5 (13) | <0.001 | 188 (42) |
| Positive | 229 (56) | 35 (87) | <0.001 | 264 (58) |
| Missing | 23 | 26 | 49 | |
| ENS | ||||
| 0–1 | 358 (80) | 53 (91) | 0.046 | 403 (82) |
| >1 | 85 (20) | 5 (9) | 90 (18) | |
| Missing | – | 8 | 8 | |
| Nodal size | ||||
| ≤6 cm | 340 (88) | 48 (87) | 0.826 | 388 (88) |
| >6 cm | 46 (12) | 7 (13) | 53 (12) | |
| Missing | 49 | 11 | 60 | |
| ECOG-PS | ||||
| 0–1 | 401 (93) | 44 (88) | 0.249 | 445 (93) |
| >1 | 30 (7) | 6 (12) | 36 (7) | |
| Missing | 4 | 16 | 20 | |
| LDH | ||||
| ≤ULN | 293 (69) | 36 (63) | 0.449 | 329 (68) |
| >UNL | 133 (31) | 21 (37) | 154 (32) | |
| Missing | 9 | 9 | 18 | |
| B2M | ||||
| ≤ULN | 132 (37) | 9 (21) | 0.042 | 171 (36) |
| >UNL | 221 (63) | 33 (79) | 254 (64) | |
| Missing | 82 | 24 | 106 | |
| Hemoglobin | ||||
| ≥12 mg/dL | 256 (59) | 29 (53) | 0.387 | 285 (58) |
| <12 g/dL | 178 (41) | 26 (47) | 204 (42) | |
| Missing | 1 | 11 | 12 | |
| ALC | ||||
| ≥1 109/L | 345 (80) | 36 (71) | 0.103 | 381 (79) |
| <1 109/L | 84 (20) | 15 (29) | 0.103 | 99 (21) |
| Missing | 6 | 15 | 21 | |
| Platelets | ||||
| ≥100 109/L | 373 (86) | 45 (82) | 0.417 | 418 (85) |
| <100 109/L | 61 (14) | 10 (18) | 71 (15) | |
| Missing | 1 | 11 | 12 | |
| MZL subtype | <0.001 | |||
| ENMZL | 188 (43) | 9 (14) | 197 (39) | |
| SMZL | 128 (29) | 38 (57) | 166 (33) | |
| NMZL | 51 (12) | 9 (14) | 60 (12) | |
| Diss. MZL | 68 (16) | 10 (15) | 78 (16) |
BM, bone marrow; ECOG, Eastern Cooperative Oncology Group; PS, performance status; ALC, absolute lymphocyte count; LDH, lactate dehydrogenase; UNL, upper normal limit; B2M, β2-microglobulin: ENS: extranodal sites; MZL: marginal zone lymphoma; ENMZL: extranodal marginal zone lymphoma: SMZL: splenic marginal zone lymphoma; NMZL: nodal marginal zone lymphoma; DissMZL: disseminated marginal zone lymphoma.
[n = ]: number of patients where the data was reported, otherwise n = 501.